TABLE I.

Clinical efficacy of approved treatments in relapsed or refractory mantle cell lymphoma (MCL)

Study	Patients with MCL	ORR (%)	CR (%)	Median PFS (months)
Acalabrutinib
Wang et al., 201814	124	81	40	NR
Ibrutinib
Advani et al., 201312	9 (of 56 total)	54	—	13.6
Wang et al., 201529	111	67	23	13.0
Dreyling et al., 201613	280	72	19	14.6
Bortezomib
Fisher et al., 200621	155	33	8	9.2
Strauss et al., 200622	24 (of 51 total)	29	4	—
Lenalidomide
Wiernik et al., 200824	15 (of 49 total)	53	7	5.6
Zinzani et al., 201323	57	35	12	8.8
Eve et al., 201325	26	31	7	3.9
Goy et al., 201326	134	26	8	4.0
Trneny et al., 201527	254	40	—	8.7
Temsirolimus
Hess et al., 200928	162	22	—	4.8
Dreyling et al., 201613	280	40	1	6.2

ORR = overall response rate; CR = complete response; PFS = progression-free survival.